Hepatitis C virus infection, cryoglobulinaemia, and beyond

Rheumatology

Volumn 46, Issue 4, 2007, Pages 572-578

  Sansonno, D ^c   Carbone, A ^a   De Re, V ^b   Dammacco, F ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B LYMPHOCYTE RECEPTOR; BELIBUMAB; CD81 ANTIGEN; COMPLEMENT COMPONENT C1Q; CORE PROTEIN; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MESSENGER RNA; MONOCLONAL ANTIBODY; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; RHEUMATOID FACTOR; RIBAVIRIN; RITUXIMAB; RNA DIRECTED RNA POLYMERASE; STEROID; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIGEN ANTIBODY COMPLEX; B CELL LYMPHOMA; B LYMPHOCYTE; CELL GROWTH; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CLONAL VARIATION; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY INFILTRATE; LYMPHOCYTE PROLIFERATION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SYSTEMIC VASCULITIS; VIRION; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION;

B-LYMPHOCYTES; CELL PROLIFERATION; CRYOGLOBULINEMIA; CRYOGLOBULINS; HEPATITIS C, CHRONIC; HUMANS; LYMPHOID TISSUE; LYMPHOMA, B-CELL; VASCULITIS;

EID: 34047118683     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel425     Document Type: Review

References (117)

1. Choo QL, Richman KH, Han JH et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451-5.
2. Cohen J. The scientific challenge of hepatitis C. Science 1999;285:26-30.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(Suppl):S21-9.
4. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6.
5. Agnello V. The aetiology of mixed cryoglobulinaemia associated with hepatitis C virus infection. Scand J Immunol 1995;42:179-84.
6. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: Autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000;20:143-57.
7. Andreone P, Zignego AL, Cursaro C et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998;129:294-8.
8. Tun HW, Krishna M, Menke DM. Hepatitis C-related posttransplant plasma cell proliferative disorder with hepatitis C virus in neoplastic plasma cells: A new posttransplant disease entity? Transplant Proc 2004;36:2692-6.
9. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: Immune complex relations. Lancet Infect Dis 2005;5:227-36.
10. Rosember S. Recent advances in molecular biology of hepatitis C virus. J Mol Biol 2001;313:451-2.
11. Kolykhalov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J Virol 1996;70:3363-71.
12. Banerjee R, Dasgupta A. Specific interaction of hepatitis C virus protease/helicase NS3 with the 3′ terminal sequences of viral postive- and neagative strand RNA. J Virol 2001;75:1708-21.
13. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003;77:3007-19.
14. Heller T, Saito S, Auerbach J et al. An in vitro model of hepatitis C virion production. Proc Natl Acad Sci USA 2005;102:2579-83.
15. Dammacco F, Sansonno D. Mixed cryoglobulinemia as a model of systemic vasculitis. Clin Rev Allergy Immunol 1997;15:97-119.
16. Maire MA, Mittey M, Lambert PH. The presence of cryoprecipitable immunoglobulins in normal human sera may reflect specific molecular interactions. Autoimmunity 1989;2:155-64.
17. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
18. Denman AM. Cryoglobulins and the immunopathological manifestations of autoimmune disease. Clin Exp Immunol 1992;87:169-71.
19. Wang AC, Wells JV, Fudenberg HH, Gergely J. Chemical analyses of cryoglobulins. Immunochemistry 1974;11:341-5.
20. Montagnino G. Reappraisal of the clinical expression of mixed cryoglobulinemia. Springer Semin Immunopathol 1988;10:1-19.
21. Gorevic PD, Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: Implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol 1991;28:79-94.
22. Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis 1998;57:3-5.
23. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: An overview. Eur J Clin Invest 2001;31:628-38.
24. Dammacco F, Sansonno D, Cornacchiulo V et al. Hepatitis C virus infection and mixed cryoglobulinemia: A striking association. Int J Clin Lab Res 1993;23:45-9.
25. Lunel F, Musset T, Cacoub P et al. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291-300.
26. Pawlosky J, Mustapha B, Andre C et al. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994;19:841-8.
27. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: An immunological perspective. Hepatology 1997;26:1375-9.
28. Monti G, Galli M, Invernizzi F et al. Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. Q J Med 1995;88:115-26.
29. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40:837-56.
30. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999;106:347-54.
31. Authier FJ, Pawlotsky JM, Viard JP, Guillevin L, Degos JD, Gherardi RK. High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. Ann Neurol 1993;34:749-50.
32. Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 1998;315:208-10.
33. Dammacco F, Sansonno D. Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. Clin Exp Immunol 1992;87:352-6.
34. Saadoun D, Asselah T, Resche-Rigon M et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitris C. Hepatology 2006;46:1337-45.
35. Ferri C, Sebastiani M, Giuggioli D et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74.
36. Saadoun D, Bieche I, Maisonobe T et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2005;52:2917-25.
37. Curry MP, Golden-Mason L, Doherty DG et al. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J Hepatol 2003;38:642-50.
38. Newkirk MM. Rheumatoid factors: Host resistance or autoimmunity? Clin Immunol 2002;104:1-32.
39. Musset L, Diemert MC, Taibi F et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802.
40. Tissot JD, Schifferli JA, Hochstrasser DF et al. Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. Immunol Methods 1994;173:63-75.
41. Pal S, Sullivan DG, Kim S et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: Implications of HCV lymphotropism. Gastroenterology 2006;130:1107-16.
42. Takkyar ST, Li D, Wang Y, Trowbridge R, Gowans EJ. Specific detection of minus-strand hepatitis C virus RNA by reverse-transcription polymerase chain reaction on PolyA(+)-purified RNA. Hepatology 2000;32:382-7.
43. Sansonno D, Tucci FA, Lauletta G et al. Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinemia. Clin Exp Immunol 2007;147:241-8.
44. Sansonno D, Lauletta G, Montrone M, Tucci FA, Nisi L, Dammacco F. Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 2006;143:288-96.
45. Petracca R, Falugi F, Galli G et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 2000;74:4824-30.
46. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-25.
47. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-71.
48. Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology 2006;348:1-12.
49. Zuckerman E, Kessel A, Slobodin G, Sabo E, Yeshurun D, Toubi E. Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection. J Virol 2003;77:10432-6.
50. Kronenberger B, Sarrazin C, Hofmann WP et al. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. J Viral Hepat 2004;11:310-8.
51. Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003;101:52-7.
52. Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005;42:491-8.
53. Lerat H, Berby F, Trabaud MA et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996;97:845-51.
54. Sansonno D, Iacobelli AR, Cornacchiulo V, Iodice G, Dammacco F. Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996;103:414-21.
55. Sansonno D, Lotesoriere C, Cornacchiulo V et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 1998;92:3328-37.
56. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160:3594-601.
57. De Vita S, De Re V, Gasparotto D et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000;43:94-102.
58. Hallas C, Greiner A, Peters K, Muller-Hermelink HK. Immunoglobulin VH genes of high-grade mucosa-associated lymphoid tissue lymphomas show a high load of somatic mutations and evidence of antigen-dependent affinity maturation. Lab Invest 1998;78:277-87.
59. Aarts WM, Bende RJ, Steenbergen EJ et al. Variable heavy chain gene analysis of follicular lymphomas: Correlation between heavy chain isotype expression and somatic mutation load. Blood 2000;95:2922-9.
60. De Re V, De Vita S, Marzotto A et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000;96:3578-84.
61. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005;201:1229-41.
62. De Re V, Sansonno D, Simula MP et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006;20:1145-54.
63. Posnett DN, Edinger J. When do microbes stimulate rheumatoid factor? J Exp Med 1997;185:1721-3.
64. Fehr T, Bachmann MF, Bucher E et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 1997;185:1785-92.
65. Mannik M. Pathophysiology of circulating immune complexes. Arthritis Rheum 1982;25:783-7.
66. Feiner HD. Relationship of tissue deposits of cryoglobulin to clinical features of mixed cryoglobulinemia, Hum Pathol 1983;14:710-5.
67. Sansonno D, Cornacchiulo V, Iacobelli AR, Di Stefano R, Lospalluti M, Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 1995;21:305-12.
68. Agnello V, Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 1997;40:2007-15.
69. Karlsberg PL, Lee WM, Casey DL, Cockerell CJ, Cruz PD. Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia. Arch Dermatol 1995;131:1119-23.
70. Sansonno D, Lauletta G, Nisi L et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 2003;133:275-82.
71. Huang DF, Olee T, Masuho Y, Matsumoto Y, Carson DA, Chen PP. Sequence analyses of three immunoglobulin G anti-virus antibodies reveal their utilization of autoantibody-related immunoglobulin Vh genes, but not V lambda genes. J Clin Invest 1992;90:2197-208.
72. Trendelenburg M, Schifferli JA. Cryoglobulins in chronic hepatitis C virus infection. Clin Exp Immunol 2003;133:153-215.
73. Theofilopoulos AN, Dixon FJ. Immune complexes in human diseases: A review. Am J Pathol 1980;100:529-94.
74. Stokol T, O'Donnell P, Xiao L et al. C1q governs deposition of circulating immune complexes and leukocyte Fc gamma receptors mediate subsequent neutrophil recruitment. J Exp Med 2004;200:835-46.
75. Feng X, Tonnesen MG, Peerschke EI, Ghebrehiwet B. Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol 2002;168:2441-8.
76. Yao ZQ, Nguyen DT, Hiotellis AI, Hahn YS. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J Immunol 2001;167:5264-72.
77. Yao ZQ, Shata MT, Tricoche N et al. gC1qR expression in chimpanzees with resolved and chronic infection: Potential role of HCV core/ gC1qR-mediated T cell suppression in the outcome of HCV infection. Virology 2006;346:324-37.
78. Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum 1988;31:99-107.
79. Thompson RA. Complement. In: Holborow EJ, Reeves WG, eds. Immunology in medicine. London: Grune & Stratton, 1983;95-119.
80. Saadoun D, Sadallah S, Trendelemburg M et al. Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol 2006;145:308-12.
81. Vallat L, Benhamou Y, Gutierrez M et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004;50:3668-78.
82. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 2001;167:21-9.
83. Sansonno D, Lauletta G, De Re V et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004;34:126-36.
84. Taneda S, Segerer S, Hudkins KL et al. Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. Am J Pathol 2001;159:2355-69.
85. Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75.
86. Schneider P, Tschopp J. BAFF and the regulation of B cell survival. Immunol Lett 2003;88:57-62.
87. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002;23:113-5.
88. Patke A, Mecklenbrauker I, Tarakhovsky A. Survival signaling in resting B cells. Curr Opin Immunol 2004;16:251-5.
89. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
90. Zignego AL, Ferri C, Giannelli F et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002;137:571-80.
91. Sansonno D, Tucci FA, De Re V et al. HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology 2005;42:1019-27.
92. Fabris M, Quartuccio L, Sacco S et al. B-Lymphocyte Stimulator (BLyS) upregulation in mixed cryoglobulinemia syndrome and hepatitis C-virus infection. Rheumatology 2007;46:37-43.
93. Sene D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation- trhe role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology 2007; 65-9.
94. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non Hodgkin's lymphoma: Systematic review and meta-analysis. Gastroenterology 2003;125:1723-32.
95. De Vita S, Sacco C, Sansonno D et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997;90:776-82.
96. Mele A, Pulsioni A, Bianco E et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study. Blood 2003;102:996-9.
97. Germanidis G, Haioun C, Dhumeaux D, Reyes F, Pawlotsky JM. Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma. Hepatology 1999;30:822-3.
98. Talamini R, Montella M, Crovatto M et al. Non-Hodgkin's lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. Int J Cancer 2004;110:380-5.
99. Hermine O, Lefrere F, Bronowicki JP et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-97.
100. Saadoun D, Suarez F, Lefrere F et al. Splenic lymphoma with villous lumphocytes associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005;105:74-6.
101. De Vita S, Sansonno D, Dolcetti R et al. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood 1995;86:1887-92.
102. Sansonno D, De Vita S, Cornacchiulo V, Carbone A, Boiocchi M, Dammacco F. Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. Blood 1996;88:4638-45.
103. Dammacco F, Gatti P, Sansonno D. Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: An emerging picture. Leuk Lymphoma 1998;31:463-76.
104. Mariette X. Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: Chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001;60:1007-10.
105. Libra M, Gasparotto D, Gloghini A, Navolanic PM, De Re V, Carbone A. Hepatitis C virus (HCV) infection and lymphoproliferative disorders. Frontiers Biosci 2005;10:2460-71.
106. Guillevin L. Virus-associated vasculitides. Rheumatology 1999;38:588-90.
107. Casato M, Laganà B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991;78:3142-7.
108. Dammacco F, Sansonno D, Han JH et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study. Blood 1994;84:3336-43.
109. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
110. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schwarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80.
111. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated Interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005;52:911-9.
112. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.
113. McLaughlin P. Rituximab: Perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol 2001;40:3-16.
114. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.
115. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
116. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999;42:2507-16.
117. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004;16:180-5.